Conrad K A, Fagan T C, Lee S M, Simons J A
Clin Pharmacol Ther. 1986 Oct;40(4):476-9. doi: 10.1038/clpt.1986.209.
The effects of tripamide and hydrochlorothiazide on blood pressure and glucose tolerance were studied in 20 hypertensive patients, half of whom had type II diabetes mellitus. Each patient underwent intravenous glucose tolerance testing before and after 4 weeks of treatment with tripamide, 10 mg, and, at a separate time, hydrochlorothiazide, 50 mg. Both tripamide and hydrochlorothiazide lowered blood pressure; for both drugs, the magnitude of the reduction in mean arterial pressure was positively correlated with the pretreatment mean arterial pressure. Hydrochlorothiazide produced a greater fall in serum potassium than did tripamide. In the nondiabetics, neither drug produced a significant change in the glucose disappearance curve or the plasma insulin response. In the diabetics, hydrochlorothiazide produced an increase in serum glucose levels, but the plasma insulin response, which was blunted in comparison to the nondiabetics, did not change. Tripamide did not affect serum glucose or plasma insulin levels in either group of patients. Tripamide at a dose of 10 mg daily does not affect glucose tolerance in either nondiabetic hypertensive patients or patients with type II diabetes mellitus.
在20例高血压患者中研究了曲帕胺和氢氯噻嗪对血压和糖耐量的影响，其中一半患者患有II型糖尿病。每位患者在接受10毫克曲帕胺治疗4周前后，以及在另外一个时间接受50毫克氢氯噻嗪治疗前后，均进行了静脉葡萄糖耐量试验。曲帕胺和氢氯噻嗪均能降低血压；对于这两种药物，平均动脉压降低的幅度与治疗前的平均动脉压呈正相关。氢氯噻嗪导致的血清钾下降幅度比曲帕胺更大。在非糖尿病患者中，两种药物均未使葡萄糖消失曲线或血浆胰岛素反应发生显著变化。在糖尿病患者中，氢氯噻嗪使血清葡萄糖水平升高，但与非糖尿病患者相比有所减弱的血浆胰岛素反应并未改变。曲帕胺对两组患者的血清葡萄糖或血浆胰岛素水平均无影响。每日剂量为10毫克的曲帕胺对非糖尿病高血压患者或II型糖尿病患者的糖耐量均无影响。
